Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry
Language English Country France Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
27638381
DOI
10.1007/s11523-016-0458-1
PII: 10.1007/s11523-016-0458-1
Knihovny.cz E-resources
- MeSH
- Phenylurea Compounds administration & dosage pharmacology therapeutic use MeSH
- Colorectal Neoplasms drug therapy pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Metastasis MeSH
- Antineoplastic Agents therapeutic use MeSH
- Pyridines administration & dosage pharmacology therapeutic use MeSH
- Registries MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Phenylurea Compounds MeSH
- Antineoplastic Agents MeSH
- Pyridines MeSH
- regorafenib MeSH Browser
OBJECTIVE: To describe the use of regorafenib for the treatment of metastatic colorectal cancer (mCRC) in clinical practice in the Czech Republic, and to describe the clinical outcomes of patients in terms of safety and survival. PATIENTS AND METHODS: The data of patients treated with regorafenib were extracted from the national CORECT registry. The CORECT registry is a non-interventional post-marketing database, gathering information about patients with CRC and treated with targeted agents. Twenty oncology centres in the Czech Republic contributed to this registry. Collected data included patients' characteristics, disease history, cancer treatments, response to treatments and safety. RESULTS: A total of 148 patients treated with regorafenib in clinical practice were analysed. At regorafenib initiation, almost all patients were fully active or slightly restricted in physical activity. Regorafenib was not administered as first-line treatment in any patient. Median progression-free survival was 3.5 months and median overall survival was 9.3 months. One-year survival rate was 44.6 %. Four partial responses were observed and 51 stable diseases. Progression was observed in 66 patients (44.6 %). The main reported adverse events were skin toxicity (5.4 %) and fatigue (2.0 %). CONCLUSIONS: Regorafenib is a well-established treatment for pretreated patients with mCRC, however real-life data are scarce. Our results demonstrated slightly better efficacy of regorafenib and better safety profile in patients with mCRC compared to the randomised trials.
Department of Oncology General Faculty Hospital Charles University Prague Czech Republic
Department of Oncology Palacky University Medical and Teaching Hospital Olomouc Czech Republic
Institute of Biostatistics and Analysis Faculty of Medicine Masaryk University Brno Czech Republic
See more in PubMed
BMC Gastroenterol. 2014 Mar 25;14:53 PubMed
Cancer Res. 2004 Oct 1;64(19):7099-109 PubMed
Lancet. 2013 Jan 26;381(9863):303-12 PubMed
Oncol Res Treat. 2015;38(6):300-8 PubMed
Lancet Oncol. 2015 Jun;16(6):619-29 PubMed
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9 PubMed
Lancet Oncol. 2015 Aug;16(8):937-48 PubMed
Br J Cancer. 2012 May 22;106(11):1722-7 PubMed
Curr Pharm Des. 2002;8(25):2255-7 PubMed
JAMA. 2009 Dec 2;302(21):2338-44 PubMed
Clin Transl Oncol. 2016 Nov;18(11):1072-1081 PubMed
Int J Cancer. 2011 Jul 1;129(1):245-55 PubMed
Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
